Probatebeta
Target

MAP2K1

Dual specificity mitogen-activated protein kinase kinase 1

As of the edition of 20 October 2026, MAP2K1 (dual specificity mitogen-activated protein kinase kinase 1, UniProt Q02750) has 20 drugs tested at it and 22 companies on the list, 8 on route A and 7 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q02750
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
100
Disease areas
Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Nervous system; Hormones; Blood and lymph; Inherited and neonatal
Registered trials of its drugs
747

Drugs at this target

StatusCount
Marketed6
Active3
Went quiet4
Stopped7
Total20
DrugStatusFurthest phaseUS protection
TrametinibMarketedPhase 4Ends 2030
BinimetinibMarketedPhase 4Ends 2033
SelumetinibMarketedPhase 3Ends 2032
CobimetinibMarketedPhase 3Ends 2036
AvutometinibMarketedPhase 3Ends 2032
MirdametinibMarketedPhase 2Ends 2041
TunlametinibActivePhase 4none listed
PimasertibStoppedPhase 2none listed
LuvometinibActivePhase 3none listed
RefametinibWent quietPhase 2none listed
E-6201StoppedPhase 2none listed
TAK-733ActivePhase 2none listed

12 of 20 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A8
Route B7
Engaged6
Undetermined1
Total on the list22
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
PfizerRoute B
AstraZenecaRoute B

The other 19 companies at MAP2K1

In the product

22 companies in all; 19 are not named here, and no score is.

See the 22 companies at MAP2K1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at MAP2K1

Other targets in cancer

Companies holding approvals at MAP2K1